• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Unique features of alloreactivity
3. Estimating frequency of alloreactive T cells in vivo
4. Alloreactive precursor frequency
5. Tolerance approaches
6. T cells costimulatory pathways
7. Blockade induces transplant tolerance
8. Distinct effects of CD28 costimulation
9. Apoptotic T cells induce transplantation tolerance
10. Calcineurin inhibition antagonizes blockade
11. Antagonism of blockade and calcineurin inhibitors
12. Reduction in T cells number facilitates tolerance
13. How to delete alloreactive cells?
14. Homeostatic proliferation
15. Homeostatic proliferation: a barrier to tolerance
16. Homeostatic proliferation and memory generation
17. Memory-like functional responses
18. Memory T cells abrogate graft prolongation
19. Cardiac allograft rejection in scid mice
20. Scid mice resist tolerance induction
21. Homeostatic proliferation of B6 T cells
22. T cells depletion leads to proliferation (1)
23. T cells depletion leads to proliferation (2)
24. Incomplete T cells depletion affects tolerance
25. Do memory cells develop due to failure to tolerize?
26. BrdU incorporation in transferred B6 T cells
27. Cardiac allograft rejection
28. Failure to maintain suppressor cells
29. % of CD4+CD25+ after homeostatic proliferation
30. T cells from reconstituted scid mice
31. Reconstituting normal mice made T-cell deficient
32. Failure to tolerize after homeostatic proliferation
33. Reduction in clonal mass facilitates tolerance
34. Heterologous immunity: a barrier to tolerance (1)
35. Heterologous immunity: a barrier to tolerance (2)
36. Memory cells in partial depletion, lymphopenia
37. Various types of cells in the aftermath of depletion
38. Differential depletion
39. Sparing of memory T cells after depletion
40. Differential proliferation
41. Testing differential proliferation
42. Proliferation of memory T cells after depletion (1)
43. Proliferation of memory T cells after depletion (2)
44. Depletion doesn't alter the proportion of CD4 cells
45. CD4+CD25+ Tregs versus non-regulatory T cells
46. Prevention of rejection of homeostatic proliferation
47. Restoring tolerance induction by Tregs
48. Restoring tolerance induction by anti-CD4/CD8
49. Anti-CD4/CD8 block homeostatic proliferation
50. Why is transplant tolerance hard to achieve?
51. Acknowledgements

Topics Covered

• Overview of alloreactivity
• Tolerance approaches
• Co-stimulatory blockade
• Requirement for cell depletion
• Homeostatic proliferation overview
• Homeostatic proliferation generates memory cells and blocks tolerance induction
• Depletion spares memory cells

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Immunology
• Methods

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. Laurence Turka has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.